Medical rehabilitation of patients with menopausal syndrome and surgical menopause: contribution of magnesium deficiency correction

Background. The increase in the proportion of patients with menopausal syndrome (MS) and surgical menopause, including women in the recovery phase after radical surgical treatment of the reproductive system cancer, is a characteristic trend of the 21st century. Part of them receive menopausal hormone therapy (MHT). This determines the relevance of the analysis of the specified cohort of patients to enhance rehabilitation programs designed to improve the quality of life (QoL) in this category of gynecological patients.

Objective: subanalysis of primary data from the MAGYN study cohort of MHT treated women with MS and surgical menopause.

Material and methods. The MAGYN observational non-interventional study of the real clinical practice included 9168 women, of whom 1528 represented a group of previously not characterized MHT treated women with MS and surgical menopause. To determine the number of patients with magnesium deficiency (MD), a Magnesium Deficiency Questionnaire (MDQ) was used, a biochemical blood test with an indicator of serum magnesium concentration was evaluated. The profile of the participants was analyzed by the presence of general somatic pathologies, obstetric, gynecological history, complaints, symptoms of MD on a visual-analog scale. The QoL was assessed with the help of The World Health Organization Quality of Life Brief Version (WHOQOL-BREF) before the start of a 4-week course of MD supplementation and after treatment.

Results. According to the MDQ results, the prevalence of DM was 79.4%, which exceeded the results of all other groups in the study. Women with MD had a higher incidence of viral infections (19.2% vs. 22.7%; p=0.028), vegetative-vascular dystonia (26.2% vs. 29.7%; p=0.0466) and osteochondrosis (42.9% vs. 46.8%; p=0.0453). A subgroup of participants with verified MD demonstrated significantly more pronounced symptoms, such as irritability (4.9±3.5 vs. 4.6±3.4 points in the general group; p=0.0437), sleep disorders (4.4±2.3 vs. 4.2±2.3 points; p=0.0491), back pain (3.9±2.0 vs. 3.7±2.0; p=0.0405), and increased fatigue (4.6±2.3 vs. 4.4±2.3 points; p=0.0444). After the end of the course of therapy with fixed dose combination of magnesium citrate and pyridoxine, the sum of MDQ scores decreased from 46.0±12.7 to 29.2±15.1 points (p<0.001) in combination with an increase in the plasma concentration of magnesium to 0.79±0.23 mmol/l; women's satisfaction with their physical, psychological, social well-being increased (from 21.1±4.5 to 26.2±3.5 points; from 24.8±4.9 to 28.1±4.4 points, and from 9.3±2.7 to 11.0±2.8 points, respectively; p<0.001); self-perception increased from 18.2±3.7 to 22.2±3.6 points. Thus, there was a significant decrease in the severity of MD and a significant improvement in QoL according to WHOQOL-BREF, which is important in the rehabilitation of such patients.

Conclusion. The profile of patients with MS and surgical menopause receiving MHT, including the period of recovery after radical surgical treatment of reproductive cancer, is characterized by MD and decreased QoL. It seems effective to introduce MD correction into the complex rehabilitation program of such patients. It is necessary to conduct further studies to improve the rehabilitation measures in this cohort of patients.

1. Blbulyan T.A., Solopova A.G., Ivanov A.E., Kurkina E.I. Effect of postoperative rehabilitation on quality of life in patients with vulvar cancer. Obstetrics, Gynecology and Reproduction. 2020; 14 (4): 415–25 (in Russ.). https://doi.org/10.17749/2313-7347/ob.gyn.rep.2020.156.

2. Stucki G., Bickenbach J., Gutenbrunner C., Melvin J. Rehabilitation: the health strategy of the 21st century. J Rehabil Med. 2018; 50 (4): 309–16. https://doi.org/10.2340/16501977-2200.

3. Solopova A.G., Idrisova L.E., Makatsariya A.D., et al. Multidisciplinary approach to medical rehabilitation of oncogynecologic patients. Obstetrics, Gynecology and Reproduction. 2017; 11 (4): 57–67 (in Russ.). https://doi.org/10.17749/2313-7347.2017.11.4.057-067.

4. Anwar S.L., Adistyawan G., Wulaningsih W., et al. Rehabilitation for cancer survivors: how we can reduce the healthcare service inequality in low-and middle-income countries. Am J Physl Med Rehabil. 2018; 97 (10) 764–71. https://doi.org/10.1097/PHM.0000000000000982.

5. Blinov D.V., Solopova A.G., Plutnitskiy A.N., et al. Strengthening health care to provide rehabilitation services for women with cancer diseases of the reproductive system. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2022; 15 (1): 119–30 (in Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.132.

6. Blinov D.V., Akarachkova E.S., Ampilogova D.M., et al. Depression in postmenopause: interdisciplinary approach in management and perspectives for rehabilitation. Obstetrics, Gynecology and Reproduction. 2021; 15 (6): 738–54 (in Russ.). https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.280.

7. Gromova O.A., Torshin I.Yu., Rudakov K.V., et al. Magnesium deficiency – a significant risk factor for comorbidity: results of large-scale screening of magnesium status in Russian regions. Farmateka. 2013; 6: 115–29 (in Russ.).

8. Porri D., Biesalski H.K., Limitone A., et al. Effect of magnesium supplementation on women’s health and well-being. NFS Journal. 2021: 23: 30–6. https://doi.org/10.1016/j.nfs.2021.03.003.

9. Makatsariya A.D., Bitsadze V.O., Khizroeva D.H., Dzhobava E.M. Prevalence of magnesium deficiency in pregnant women. Gynecology, Obstetrics and Perinatology. 2012; 11 (5): 25–35 (in Russ.).

10. Blinov D.V., Solopova A.G., Achkasov E.E., et al. The role of magnesium deficiency correction in the rehabilitation of women with menopausal syndrome and surgical menopause: results of the MAGYN study. Obstetrics, Gynecology and Reproduction. 2022; 16 (6): 676–91 (in Russ.). https://doi.org/10.17749/2313-7347/ob.gyn.rep.2022.371.

11. Sung H., Ferlay J., Siegel R.L., et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71 (3): 209–49. https://doi.org/10.3322/caac.21660.

12. Soerjomataram I., Bray F. Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070. Nat Rev Clin Oncol. 2021; 18 (10): 663–72. https://doi.org/10.1038/s41571-021-00514-z.

13. Gromova O.A., Limanova O.A., Torshin I.Yu. Systematic analysis of fundamental and clinical research, as justification for the use of estrogen- containing drugs with the preparations of magnesium and pyridoxine. Obstetrics, Gynecology and Reproduction. 2013; 7 (3): 35–50 (in Russ.).

14. Kolbin A.S., Gomon Yu.M., Kasimova A.R., et al. The real practice of clinical and economic research of drugs included in the Federal Program of High-Cost Nosologies. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2022; 15 (1): 87–105 (in Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.107.

15. Blinov D.V., Solopova A.G., Plutnitskiy A.N., et al. Strengthening health care to provide rehabilitation services for women with cancer diseases of the reproductive system. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2022; 15 (1): 119–30 (in Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.132.

16. Blinov D.V., Solopova A.G., Sandzhieva L.N., et al. Strengthening medical rehabilitation services in health system: a situation analysis. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2022; 15 (2): 237–49 (in Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.140.

17. Makatsariya A.D., Dzhobava E.M., Bitsadze V.O., et al. Observational study of outpatient women in hormone dependent conditions with magnesium deficiency and receiving Magne B6® Forte in Russia (MAGYN Study). Magnes Res. 2016; 29 (3): 82.

18. Serov V.N., Baranov I.I., Blinov D.V., et al. Results of the study of magnesium deficiency in patients with hormone-dependent diseases. Obstetrics and Gynecology. 2015; 6: 91–7 (in Russ.).

19. Blinov D.V., Zimovina J.V., Sandakova E.A., Ushakova T.I. Magnesium deficiency of patients with hormone dependent diseases: pharmacoepidemiological profile and life quality assessment. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2015; 8 (2): 16–24 (in Russ.). https://doi.org/10.17749/2070-4909.2015.8.2.016-024.

20. Blinov D.V., Ushakova T.I., Makatsariya N.A., et al. Hormonal contraception and magnesium deficiency: a subanalysis of the MAGYN Study. Obstetrics, Gynecology and Reproduction. 2017; 11 (1): 36–48 (in Russ.). https://doi.org/10.17749/2313-7347.2017.11.1.036-048.

21. Serov V.N., Blinov D.V., Zimovina U.V., Dzhobava E.M. Results of the study of magnesium deficiency prevalence in pregnant women. Obstetrics and Gynecology. 2014; 6: 33–40 (in Russ.).

22. Guerrero-Romero F., Rodríguez-Morán M. Low serum magnesium levels and metabolic syndrome. Acta Diabetol. 2002; 39 (4): 209–13. https://doi.org/10.1007/s005920200036.

23. Durlach J. Recommended dietary amounts of magnesium: Mg RDA. Magnes Res. 1989; 2 (3): 195–203.

24. DiNicolantonio J.J., O'Keefe J.H., Wilson W. Subclinical magnesium deficiency: a principal driver of cardiovascular disease and a public health crisis. Open Heart. 2018; 5 (1): e000668. https://doi.org/10.1136/openhrt-2017-000668.

25. Olza J., Aranceta-Bartrina J., González-Gross M., et al. Reported dietary intake, disparity between the reported consumption and the level needed for adequacy and food sources of calcium, phosphorus, magnesium and vitamin D in the Spanish population: findings from the ANIBES study. Nutrients. 2017; 9 (2): 168. https://doi.org/10.3390/nu9020168.

26. Mazidi M., Rezaie P., Banach M. Effect of magnesium supplements on serum C-reactive protein: a systematic review and meta-analysis. Arch Med Sci. 2018; 14 (4): 707–16. https://doi.org/10.5114/aoms.2018.75719.

27. Sung M.K., Lee U.S., Ha N.H., et al. A potential association of meditation with menopausal symptoms and blood chemistry in healthy women: a pilot cross-sectional study. Medicine (Baltimore). 2020; 99 (36): e22048. https://doi.org/10.1097/MD.0000000000022048.

28. Simon J.A., Kokot-Kierepa M., Goldstein J., Nappi R.E. Vaginal health in the United States: results from the Vaginal Health: Insights, Views, & Attitudes survey. Menopause. 2013; 20 (10): 1043–8. https://doi.org/10.1097/GME.0b013e318287342d.

29. Krychman M., Graham S., Bernick B., et al. The Women’s EMPOWER survey: women’s knowledge and awareness of treatment options for vulvar and vaginal atrophy remains inadequate. J Sex Med. 2017; 14 (3): 425–33. https://doi.org/10.1016/j.jsxm.2017.01.011.

30. Ngai F.W. Relationships between menopausal symptoms, sense of coherence, coping strategies, and quality of life. Menopause. 2019; 26 (7): 758–64. https://doi.org/10.1097/GME.0000000000001299.

31. Gröber U., Schmidt J., Kisters K. Magnesium in prevention and therapy. Nutrients. 2015; 7 (9): 8199–226. https://doi.org/10.3390/nu7095388.

32. Sun C., Wang R., Li Z., Zhang D. Dietary magnesium intake and risk of depression. J Affect Disord. 2019; 246: 627–32. https://doi.org/10.1016/j.jad.2018.12.114.

33. Szkup M., Jurczak A., Brodowska A., et al. Analysis of relations between the level of Mg, Zn, Ca, Cu, and Fe and depressiveness in postmenopausal women. Biol Trace Elem Res. 2017; 176 (1): 56–63. https://doi.org/10.1007/s12011-016-0798-9.

34. Phelan D., Molero P., Martínez-González M.A., Molendijk M. Magnesium and mood disorders: systematic review and meta-analysis. B J Psych Open. 2018; 4 (4): 167–79. https://doi.org/10.1192/bjo.2018.22.